(Q36584375)

15 August 2017

1 reference

title

Chapter 19: Cost-effectiveness of cervical cancer screening (English)

1 reference

cost-effectiveness analysis

15 August 2017

main subject

1 reference

based on heuristic

inferred from title

cervix uterine cancer

1 reference

1

Sue J Goldie

1 reference

15 August 2017

Jane J Kim

2

1 reference

15 August 2017

Evan Myers

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

22 June 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

24 Suppl 3

1 reference

15 August 2017

page(s)

S3/164-70

1 reference

Chapter 15: Public health policy and cost-effectiveness analysis.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.114

Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.114

Costs and effectiveness of alternative strategies for cervical cancer screening in military beneficiaries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.114

Cost-Effectiveness of Cervical Cancer Screening: Comparison of Screening Policies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.114

Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.114

Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.114

An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.114

Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.114

Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.114

Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.114

The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.114

Benefits and costs of using HPV testing to screen for cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.114

The planning of cervical cancer screening programmes in eastern Europe: is viral testing a suitable alternative to smear testing?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.114

Evaluating cervical cancer screening programmes for developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.114

Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.114

Costs and benefits of different strategies to screen for cervical cancer in less-developed countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.114

Cost-effectiveness of cervical-cancer screening in five developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.114

Overview of important cervical cancer screening process values in European Union (EU) countries, and tentative predictions of the corresponding effectiveness and cost-effectiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.114

The balance of harms, benefits, and costs of screening for cervical cancer in older women: the case for continued screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.114

Early withdrawal from cervical cancer screening: the question of cost-effectiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.114

Lifetime effects, costs, and cost effectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: results of the NHS pilot studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.114

Setting the target for a better cervical screening test: characteristics of a cost-effective test for cervical neoplasia screening*1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.114

Impact of increasing Papanicolaou test sensitivity and compliance: a modeled cost and outcomes analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.114

An alternative cost effectiveness analysis of ThinPrep in the Australian setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.114

10.1016/J.VACCINE.2006.05.114

7 January 2021

Identifiers

DOI

1 reference

15 August 2017

1 reference